Your search returned 2 results.

Results
	1.	Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. [electronic resource] by Lee, Dae Ho Lee, Jung Shin Kim, Sang-We Rodrigues-Pereira, José Han, Baohui Song, Xiang-Qun Wang, Jie Kim, Hoon-Kyo Sahoo, Tarini Prasad Digumarti, Raghunadharao Wang, Xin Altug, Sedat Orlando, Mauro Producer: 20140506 In: European journal of cancer (Oxford, England : 1990) vol. 49 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. [electronic resource] by Zhao, Hong-Yun Chen, Gong-Yan Huang, Yan Li, Xiao-Li Feng, Ji-Feng Shi, Mei-Qi Cheng, Ying Ma, Li-Xia Zhang, Yi-Ping Gu, Cui-Ping Song, Xiang-Qun Zhou, Da Zhang, Li Producer: 20150410 In: Medicine vol. 94 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search